These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

801 related articles for article (PubMed ID: 17197367)

  • 1. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder.
    Mehler-Wex C; Riederer P; Gerlach M
    Neurotox Res; 2006 Dec; 10(3-4):167-79. PubMed ID: 17197367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine and the regulation of cognition and attention.
    Nieoullon A
    Prog Neurobiol; 2002 May; 67(1):53-83. PubMed ID: 12126656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update.
    Prince J
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S39-45. PubMed ID: 18480676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Changes in neural networks by conditional transgenic approach: a key to our comprehension of neuro-psychiatric disorders in the basal ganglia system].
    Schiffmann SN
    Bull Mem Acad R Med Belg; 2009; 164(7-9):171-8; discussion 178-80. PubMed ID: 20218186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Striatal sensitivity during reward processing in attention-deficit/hyperactivity disorder.
    Paloyelis Y; Mehta MA; Faraone SV; Asherson P; Kuntsi J
    J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):722-732.e9. PubMed ID: 22721595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of phenylketonuria with attention deficit hyperactivity disorder: do markedly different aetiologies deliver common phenotypes?
    Stevenson M; McNaughton N
    Brain Res Bull; 2013 Oct; 99():63-83. PubMed ID: 24140048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity.
    Jucaite A; Fernell E; Halldin C; Forssberg H; Farde L
    Biol Psychiatry; 2005 Feb; 57(3):229-38. PubMed ID: 15691523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine transporter density in the basal ganglia assessed with [123I]IPT SPET in children with attention deficit hyperactivity disorder.
    Cheon KA; Ryu YH; Kim YK; Namkoong K; Kim CH; Lee JD
    Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):306-11. PubMed ID: 12552351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attention deficit/hyperactivity disorder: is there a correlation between dopamine transporter density and cerebral blood flow?
    da Silva N; Szobot CM; Anselmi CE; Jackowski AP; Chi SM; Hoexter MQ; Anselmi OE; Pechansky F; Bressan RA; Rohde LA
    Clin Nucl Med; 2011 Aug; 36(8):656-60. PubMed ID: 21716015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chapter 33: the history of movement disorders.
    Lanska DJ
    Handb Clin Neurol; 2010; 95():501-46. PubMed ID: 19892136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basal ganglia, movement disorders and deep brain stimulation: advances made through non-human primate research.
    Wichmann T; Bergman H; DeLong MR
    J Neural Transm (Vienna); 2018 Mar; 125(3):419-430. PubMed ID: 28601961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Structural and functional neuroanatomy of attention-deficit hyperactivity disorder (ADHD)].
    Emond V; Joyal C; Poissant H
    Encephale; 2009 Apr; 35(2):107-14. PubMed ID: 19393378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased risk of diseases of the basal ganglia and cerebellum in patients with a history of attention-deficit/hyperactivity disorder.
    Curtin K; Fleckenstein AE; Keeshin BR; Yurgelun-Todd DA; Renshaw PF; Smith KR; Hanson GR
    Neuropsychopharmacology; 2018 Dec; 43(13):2548-2555. PubMed ID: 30209407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schizophrenia and Parkinson's disease lead to equal motor-related changes in cortical and subcortical brain activation: an fMRI fingertapping study.
    Müller JL; Deuticke C; Putzhammer A; Röder CH; Hajak G; Winkler J
    Psychiatry Clin Neurosci; 2003 Dec; 57(6):562-8. PubMed ID: 14629703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders.
    Nikolaus S; Antke C; Müller HW
    Behav Brain Res; 2009 Dec; 204(1):32-66. PubMed ID: 19523495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neurotransmission in developmental disorders].
    Takeuchi Y
    No To Hattatsu; 2008 Nov; 40(6):451-5. PubMed ID: 19039985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Alterations in the pattern of dopaminergic markers in attention-deficit/hyperactivity disorder].
    Díaz-Heijtz R; Mulas F; Forssberg H
    Rev Neurol; 2006 Feb; 42 Suppl 2():S19-23. PubMed ID: 16555214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiology of Parkinson's disease: from clinical neurology to basic neuroscience and back.
    Bergman H; Deuschl G
    Mov Disord; 2002; 17 Suppl 3():S28-40. PubMed ID: 11948753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Parkinson's disease with symptoms of attention deficit hyperactivity disorder in childhood.
    Walitza S; Melfsen S; Herhaus G; Scheuerpflug P; Warnke A; Müller T; Lange KW; Gerlach M
    J Neural Transm Suppl; 2007; (72):311-5. PubMed ID: 17982908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease.
    Obeso JA; Rodríguez-Oroz MC; Benitez-Temino B; Blesa FJ; Guridi J; Marin C; Rodriguez M
    Mov Disord; 2008; 23 Suppl 3():S548-59. PubMed ID: 18781672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.